Beta2 Adrenergic Agonist Structural Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current β2 adrenergic receptor agonists have limitations in potency, selectivity, onset, and duration of action, as well as safety margins, necessitating the development of improved agents for treating pulmonary diseases, pre-term labor, glaucoma, and other disorders.
Innovation Solution
Development of novel β2 adrenergic receptor agonist compounds of formula (I), which include specific structural features such as various substituents and functional groups, and their use in pharmaceutical compositions and methods for treating associated diseases, along with synthetic processes and intermediates for their preparation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current β2 adrenergic receptor agonists are used, then treatment of pulmonary diseases is achieved, but potency and duration of action are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of β2 adrenergic receptor agonists through systematic variation of substituents at positions R1-R6 and ring structures. This structural parameter optimization enables compounds with both high potency (low nM IC50 values) and extended duration of action, resolving the contradiction between these two performance parameters.
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups (hydroxyl, amino, carbonyl, and various substituent patterns) within a single agonist molecule. These composite structures achieve synergistic effects that simultaneously improve both potency and duration of action beyond what single-functional-group compounds can provide.
2Reliability
If current β2 adrenergic receptor agonists are used, then therapeutic effect is achieved, but selectivity is limited
Solution Approach 1:
The patent implements local quality by introducing specific substituent patterns at defined positions (R3 as halogen or sulfone groups, R4 as hydrogen or alkyl) while maintaining the core pharmacophore. These localized structural modifications enhance selectivity for β2 receptors without compromising the overall therapeutic effect, allowing differentiation from non-selective agonists.
3Reliability
If current β2 adrenergic receptor agonists are used, then treatment is provided, but safety margins are insufficient
Solution Approach 1:
The invention segments the molecular structure into distinct functional regions with specific substituents (R1-R6 groups) that can be independently optimized. This segmentation allows separate optimization of safety-related properties (through specific substituent choices) and therapeutic properties (through core structure maintenance), thereby expanding the therapeutic window and improving safety margins.
Data Source
AI summary
The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the BETA2 adrenergic receptor.